Press Releases Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
26.08 ^USD	-1.25%		-15.82%	+28.79%

10/06	Transcript : Tarsus Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 02:00 PM
31/05	Certain Restricted Stock Units of Tarsus Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tarsus to Participate in Upcoming Investor Conferences	30/05	GL
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference	10/05	GL
Tarsus Pharmaceuticals : Corporate Presentation	09/05	PU
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements	09/05	GL
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024	02/05	GL
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	23/04	AQ
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon	23/04	GL
Tarsus Pharmaceuticals : Corporate Presentation	20/03	PU
Tarsus to Participate at Upcoming Investor Conferences	06/03	GL
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis	05/03	GL
Tarsus Announces Pricing of $100.0 Million Public Offering	01/03	GL
Tarsus Announces Proposed $100.0 Million Public Offering	01/03	GL
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements	27/02	GL
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease	22/02	GL
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease	22/02	AQ
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024	21/02	GL
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024	21/02	AQ
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference	01/02	GL
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference	01/02	AQ
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites	11/12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Press Releases

Filters